OPKO Health, Inc. Repayments of Convertible Debt
OPKO Health, Inc. (OPK) reported Repayments of Convertible Debt of $62.21 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfConvertibleDebt · last filed 2026-02-26
- OPKO Health, Inc. repayments of convertible debt for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- OPKO Health, Inc. repayments of convertible debt for the quarter ending 2024-12-31 was $25.22M.
- OPKO Health, Inc. repayments of convertible debt for the quarter ending 2023-12-31 was $0.00.
- OPKO Health, Inc. repayments of convertible debt for fiscal 2025 was $62.21M, a 106.66% increase from fiscal 2024.
- OPKO Health, Inc. repayments of convertible debt for fiscal 2024 was $30.10M.
- OPKO Health, Inc. repayments of convertible debt for fiscal 2023 was $0.00.
- OPKO Health, Inc. repayments of convertible debt for fiscal 2022 was $0.00.
| Period end | Repayments of Convertible Debt 3 month | Repayments of Convertible Debt 9 month | Repayments of Convertible Debt 12 month |
|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $62.21M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $62.21M 10-Q · filed 2025-10-29 | ||
| 2024-12-31 | $25.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $30.10M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $4.88M 10-Q · filed 2025-10-29 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | ||
| 2022-12-31 | $0.00 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |